Applications of the hCD47/hSIRPα mouse model

Useful applications for researchers working in different biomedical fields, such as immuno-oncologyinflammation and autoimmunity:

  • Assess the efficacy of CD47- and/or SIRPα-targeting therapeutics
    • Perform tumor growth inhibition assays in the context of monotherapies or combotherapies
  • Evaluate the safety and toxicity of compounds
  • Analyze the biodistribution of CD47- and/or SIRPα-targeting compounds
  • Investigate the mode of action (MoA) of CD47- and/or SIRPα-targeting compounds and understand their therapeutic potential

Features

  • Expression of different human CD47 and human SIRPα isoforms
  • Physiological regulation and expression patterns of the human CD47 and human SIRPα
  • Preservation of the target-ligand interaction
  • Fully functional mouse immune system
  • Lack of expression of the murine target genes, thus avoiding cross-reactivity

Related resources and publications

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No results

Validation data

Discover related products to

hCD47/hSIRPα

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Immune checkpoint
PD-1
GITR
ICP (multi-target)
GITRL

genO-hPD-1/hGITR/hGITRL

The genO-hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

CD137
ICP (single-target)
Immune checkpoint

hCD137

hCD137 immunocompetent mice enable the efficacy assessment of anti-CD137.

Immune checkpoint
CD28
ICP (single-target)
T-cell engager

hCD28

The hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

Immune checkpoint
CD39
ICP (single-target)

hCD39

The hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
ICP (single-target)

hCTLA-4

The hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

Immune checkpoint
CTLA-4
Lag3
ICP (multi-target)

hCTLA-4/hLAG3

The hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
GITR
ICP (single-target)

hGITR

The hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

Immune checkpoint
GITR
GITRL
ICP (multi-target)

hGITR/hGITRL

The hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

Immune checkpoint
OX40
ICP (single-target)

hOX40

The hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint OX40 in fully immunocompetent mice.

PD-1
Immune checkpoint
ICP (single-target)

hPD-1

The hPD‑1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

Immune checkpoint
CTLA-4
PD-1
ICP (multi-target)

hPD-1/hCTLA-4

The hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

Immune checkpoint
PD-1
PD-L1
ICP (multi-target)

hPD-1/hPD-L1

The hPD‑1/hPD‑L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

Immune checkpoint
PD-1
TIM3
ICP (multi-target)

hPD-1/hTIM3

The hPD-1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

Immune checkpoint
PD-1
VISTA
ICP (multi-target)

hPD-1/hVISTA

The hPD-1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

Immune checkpoint
PD-1
Lag3
ICP (multi-target)

hPD‑1/hLAG3

The hPD‑1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

Immune checkpoint
VISTA
ICP (single-target)

hVISTA

The hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

MC38
Immune checkpoint
PD-L1
CD47

MC38-hPD-L1-hCD47-LZ

The MC38-hPD-L1-hCD47-LZ clonal cell line expresses high levels of human PD-L1 and human CD47.

Preclinical double-humanized CD47/hSIRPα model

Get in touch about

Let us know how we can help